Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:24 | 2026-04-01 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | SALE | $31.05 | 1,000 | $31,050 | 68,747 | -1.4% |
| 2026-04-03 20:00 | 2026-04-01 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | Biological Products, (No Diagnostic Substances) | SALE | $51.00 | 1,000 | $51,000 | 25,722 | -3.7% |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $85.01 | 2,000 | $170,020 | 177,371 | -1.1% |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $84.84 | 5,500 | $466,619 | 208,398 | -2.6% |
| 2026-04-03 21:55 | 2026-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | SALE | $3.87 | 11,511 | $44,548 | 472,549 | -2.4% |
| 2026-04-03 20:33 | 2026-04-02 | IMVT | Immunovant, Inc. | Venker Eric | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $24.10 | 14,229 | $342,855 | 19,561 | -42.1% |
| 2026-04-03 20:06 | 2026-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer; CHIEF OPERATING OFFICER | Biological Products, (No Diagnostic Substances) | SALE | $58.43 | 2,250 | $131,476 | 162,994 | -1.4% |
| 2026-04-03 11:29 | 2026-04-01 | CGEN | COMPUGEN LTD | Ophir Eran | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $2.21 | 5,625 | $12,413 | 11,375 | -33.1% |
| 2026-04-03 11:31 | 2026-04-01 | CGEN | COMPUGEN LTD | Levine Zurit | Officer; SVP, Business Development | Biological Products, (No Diagnostic Substances) | OPT+S | $2.20 | 3,500 | $7,700 | 29,375 | -10.6% |
| 2026-04-02 20:06 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | Officer; SVP, Finance | Biological Products, (No Diagnostic Substances) | OPT+S | $29.44 | 2,500 | $73,611 | 12,965 | -16.2% |
| 2026-04-02 20:08 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer; President, R&D & CMO | Biological Products, (No Diagnostic Substances) | OPT+S | $29.46 | 15,000 | $441,905 | 0 | -100.0% |
| 2026-04-02 20:47 | 2026-03-31 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | Officer; SVP, Chief Technical Officer | Biological Products, (No Diagnostic Substances) | SALE | $2.50 | 2,867 | $7,168 | 195,338 | -1.4% |
| 2026-04-03 00:26 | 2026-04-02 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $39.92 | 30,000 | $1,197,489 | 183,316 | -14.1% |
| 2026-04-02 23:16 | 2026-04-01 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biological Products, (No Diagnostic Substances) | OPT+S | $14.53 | 38,120 | $553,693 | 447,202 | -7.9% |
| 2026-04-02 22:28 | 2026-04-01 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer; PRESIDENT AND CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $64.81 | 40,000 | $2,592,236 | 767,780 | -5.0% |
| 2026-04-02 20:05 | 2026-04-01 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Officer; Chief R&D Officer | Biological Products, (No Diagnostic Substances) | SALE | $5.26 | 22,598 | $118,865 | 95,961 | -19.1% |
| 2026-04-02 20:05 | 2026-04-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $6.31 | 10,946 | $69,069 | 113,856 | -8.8% |
| 2026-04-02 14:46 | 2026-04-01 | VIR | Vir Biotechnology, Inc. | SATO VICKI L | Director | Biological Products, (No Diagnostic Substances) | SALE | $9.07 | 22,000 | $199,617 | 1,100,391 | -2.0% |
| 2026-04-01 20:12 | 2026-03-30 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer; CSBO | Biological Products, (No Diagnostic Substances) | OPT+S | $29.34 | 7,500 | $220,019 | 10,503 | -41.7% |
| 2026-04-01 23:00 | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $85.43 | 22,240 | $1,900,048 | 61,202 | -26.7% |
| 2026-04-01 23:00 | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $85.39 | 12,000 | $1,024,661 | 0 | -100.0% |
| 2026-04-01 22:32 | 2026-03-30 | BEAM | Beam Therapeutics Inc. | Evans John M. | Director, Officer; CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $22.57 | 50,000 | $1,128,315 | 986,667 | -4.8% |
| 2026-04-01 11:51 | 2026-03-31 | CRIS | CURIS INC | KAITIN KENNETH I | Director | Biological Products, (No Diagnostic Substances) | BUY | $0.55 | 10,000 | $5,487 | 11,407 | +710.7% |
| 2026-03-31 22:56 | 2026-03-27 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biological Products, (No Diagnostic Substances) | OPT+S | $13.14 | 57,180 | $751,305 | 455,878 | -11.1% |
| 2026-03-31 20:05 | 2026-03-27 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.06 | 11,850 | $60,019 | 2,471,850 | +0.5% |
| 2026-03-30 21:59 | 2026-03-27 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Biological Products, (No Diagnostic Substances) | SALE | $136.82 | 10,000 | $1,368,162 | 642,567 | -1.5% |
| 2026-03-30 22:04 | 2026-03-26 | CGEN | COMPUGEN LTD | Levine Zurit | Officer; SVP, Business Development | Biological Products, (No Diagnostic Substances) | OPT+S | $2.04 | 11,875 | $24,187 | 29,375 | -28.8% |
| 2026-03-30 21:29 | 2026-03-26 | SLXN | Silexion Therapeutics Corp | Shirvan Mitchell | Officer; CSO and CDO | Biological Products, (No Diagnostic Substances) | SALE | $1.36 | 22,818 | $31,032 | 27,889 | -45.0% |
| 2026-03-30 12:46 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | Chevallard Daniel R. | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | BUY | $8.57 | 7,500 | $64,275 | 12,886 | +139.2% |
| 2026-03-30 12:46 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | Schimmelpennink Evert B. | Director, Officer; President, CEO and Secretary | Biological Products, (No Diagnostic Substances) | BUY | $8.95 | 28,089 | $251,411 | 77,289 | +57.1% |
| 2026-03-30 12:47 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | George Jeffrey P. | Director | Biological Products, (No Diagnostic Substances) | BUY | $8.92 | 5,592 | $49,890 | 5,592 | +100.0% |
| 2026-03-28 00:00 | 2026-03-25 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $85.00 | 2,000 | $170,000 | 179,371 | -1.1% |
| 2026-03-27 00:04 | 2026-03-25 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | OPT+S | $95.56 | 37,450 | $3,578,819 | 54,400 | -40.8% |
| 2026-03-27 00:05 | 2026-03-24 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | BUY | $1.23 | 900 | $1,110 | 274,766 | +0.3% |
| 2026-03-26 23:41 | 2026-03-24 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biological Products, (No Diagnostic Substances) | OPT+S | $14.03 | 57,180 | $802,235 | 468,892 | -10.9% |
| 2026-03-26 22:57 | 2026-03-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.41 | 20,082 | $108,632 | 2,460,000 | +0.8% |
| 2026-03-26 00:02 | 2026-03-23 | SRZN | Surrozen, Inc./DE | TCG Crossover GP II, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $24.72 | 121,881 | $3,012,764 | 736,547 | +19.8% |
| 2026-03-25 21:15 | 2026-03-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $78.02 | 115,977 | $9,048,294 | 61,202 | -65.5% |
| 2026-03-25 20:36 | 2026-03-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | Biological Products, (No Diagnostic Substances) | SALE | $3.25 | 40,000 | $130,000 | 906,556 | -4.2% |
| 2026-03-25 20:05 | 2026-03-23 | VCEL | Vericel Corp | Hagen Heidi | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $32.41 | 15,000 | $486,150 | 31,850 | -32.0% |
| 2026-03-24 20:02 | 2026-03-20 | BCRX | BIOCRYST PHARMACEUTICALS INC | HEGGIE THERESA | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $10.11 | 49,933 | $504,823 | 65,352 | -43.3% |
| 2026-03-24 20:35 | 2026-03-23 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | Officer; SVP, Chief Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $9.12 | 7,711 | $70,324 | 61,902 | -11.1% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $43.79 | 354 | $15,500 | 137,903 | -0.3% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Green Paula | Officer; SVP of Human Resources | Biological Products, (No Diagnostic Substances) | SALE | $43.79 | 297 | $13,005 | 124,104 | -0.2% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | SALE | $43.79 | 1,742 | $76,276 | 858,887 | -0.2% |
| 2026-03-25 01:12 | 2026-03-24 | MGTX | MeiraGTx Holdings plc | Forbes Alexandria | Director, Officer; PRESIDENT & CEO | Biological Products, (No Diagnostic Substances) | SALE | $7.41 | 62,000 | $459,420 | 1,449,695 | -4.1% |
| 2026-03-24 22:30 | 2026-03-20 | FDMT | 4D Molecular Therapeutics, Inc. | Gupta Ashoo | Officer; VP, Finance and Controller | Biological Products, (No Diagnostic Substances) | OPT+S | $8.61 | 390 | $3,358 | 47,055 | -0.8% |
| 2026-03-24 21:37 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Prasad Raju | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $46.78 | 3,708 | $173,460 | 15,565 | -19.2% |
| 2026-03-24 21:37 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $46.78 | 10,020 | $468,736 | 255,501 | -3.8% |
| 2026-03-24 21:38 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | Officer; General Counsel and Secretary | Biological Products, (No Diagnostic Substances) | OPT+S | $46.78 | 3,182 | $148,854 | 94,308 | -3.3% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.